AB-16B5

DRUG2 trials

Sponsors

Alethia Biotherapeutics

Conditions

Metastatic CancerNSCLC Stage IVSolid Tumor

Phase 1

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

CompletedNCT02412462

Alethia BiotherapeuticsMetastatic Cancer, Solid Tumor

Start: 2015-04-30End: 2017-01-31Updated: 2017-06-28

Phase 2

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

CompletedNCT04364620

Alethia BiotherapeuticsNSCLC Stage IV

Start: 2021-02-23End: 2023-12-31Updated: 2025-04-06

Related Papers

A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies

Cancer Research2017-07-013 citations